Press Release

Neurodon Receives Funding from Elevate Ventures

January 4, 2019

Neurodon Receives Funding from Elevate Ventures Through the 21st Century Research & Technology Fund

Press Release - Elevate Ventures providing funding to Neurodon

Neurodon, an Indiana-based biotech company, has received a Phase I Small Business Technology Transfer (STTR) grant from the NIH to advance their small molecule Alzheimer’s disease drug discovery program.

We’re excited to join Elevate’s portfolio

This program is funded by the state of Indiana’s 21st Century Research & Technology Fund. Eligible Indiana-based companies that have received SBIR/STTR funding are eligible to apply for the program that provides 50% matching funds.

“We’re excited to join the Elevate portfolio and are grateful for their support of Indiana companies,” said Dr. Russell Dahl, Neurodon’s CEO. “These non-dilutive funds from the state of Indiana will allow us to complete critical studies beyond the scope of our original STTR grant and position us favorably for Phase II STTR/SBIR funding from NIH. As an Indiana-based biotech company, we appreciate the resources of the Elevate ecosystem, and we look forward to a relationship with their team.”

About Elevate Ventures

Elevate Ventures is committed to developing high-performing, high-growth, Indiana-based businesses. They accomplish this by providing investment capital to Indiana entrepreneurs and robust investment opportunities to funders, and by making value-added services available to entrepreneurs.

A Story Worth Sharing

About Neurodon

Neurodon is developing disease-modifying drugs for diabetes, neurodegeneration, and other life-threatening diseases. Neurodon deploys its proprietary endoplasmic reticulum (ER) stress-based technology platform to discover small molecules that can reduce the cellular dysfunction that is the root cause of many diseases.

Press Release

September 24, 2018

Neurodon Awarded Phase I NIH Small Business Technology Transfer Grant

Advancing our small molecule Alzheimer’s disease drug discovery program.

READ THIS ARTICLE